280 related articles for article (PubMed ID: 36897017)
21. The use of antivirals in the treatment of human monkeypox outbreaks: a systematic review.
Shamim MA; Padhi BK; Satapathy P; Veeramachaneni SD; Chatterjee C; Tripathy S; Akhtar N; Pradhan A; Dwivedi P; Mohanty A; Rodriguez-Morales AJ; Sah R; Al-Tammemi AB; Al-Tawfiq JA; Nowrouzi-Kia B; Chattu VK
Int J Infect Dis; 2023 Feb; 127():150-161. PubMed ID: 36470502
[TBL] [Abstract][Full Text] [Related]
22. A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak.
Almehmadi M; Allahyani M; Alsaiari AA; Alshammari MK; Alharbi AS; Hussain KH; Alsubaihi LI; Kamal M; Alotaibi SS; Alotaibi AN; Aldhafeeri AA; Imran M
Viruses; 2022 Aug; 14(9):. PubMed ID: 36146675
[TBL] [Abstract][Full Text] [Related]
23. Update on monkeypox virus infection: Focusing current treatment and prevention approaches.
Dhapola R; Kumari S; Sharma P; KumarKushawaha P; HariKrishnaReddy D
Fundam Clin Pharmacol; 2024 Jun; 38(3):465-478. PubMed ID: 38226405
[TBL] [Abstract][Full Text] [Related]
24. Monkeypox treatment: Current evidence and future perspectives.
Khani E; Afsharirad B; Entezari-Maleki T
J Med Virol; 2023 Jan; 95(1):e28229. PubMed ID: 36253931
[TBL] [Abstract][Full Text] [Related]
25. Monkeypox (mpox) virus: Classification, origin, transmission, genome organization, antiviral drugs, and molecular diagnosis.
Karagoz A; Tombuloglu H; Alsaeed M; Tombuloglu G; AlRubaish AA; Mahmoud A; Smajlović S; Ćordić S; Rabaan AA; Alsuhaimi E
J Infect Public Health; 2023 Apr; 16(4):531-541. PubMed ID: 36801633
[TBL] [Abstract][Full Text] [Related]
26. Repositioning potentials of smallpox vaccines and antiviral agents in monkeypox outbreak: A rapid review on comparative benefits and risks.
Islam MR; Hossain MJ; Roy A; Hasan AHMN; Rahman MA; Shahriar M; Bhuiyan MA
Health Sci Rep; 2022 Sep; 5(5):e798. PubMed ID: 36032515
[TBL] [Abstract][Full Text] [Related]
27. Prevention and Treatment of Monkeypox.
Rizk JG; Lippi G; Henry BM; Forthal DN; Rizk Y
Drugs; 2022 Jun; 82(9):957-963. PubMed ID: 35763248
[TBL] [Abstract][Full Text] [Related]
28. Breaking Barriers: Current Advances and Future Directions in Mpox Therapy.
Shah BM; Modi P
Curr Drug Targets; 2024; 25(1):62-76. PubMed ID: 38151842
[TBL] [Abstract][Full Text] [Related]
29. Interim Clinical Treatment Considerations for Severe Manifestations of Mpox - United States, February 2023.
Rao AK; Schrodt CA; Minhaj FS; Waltenburg MA; Cash-Goldwasser S; Yu Y; Petersen BW; Hutson C; Damon IK
MMWR Morb Mortal Wkly Rep; 2023 Mar; 72(9):232-243. PubMed ID: 36862595
[TBL] [Abstract][Full Text] [Related]
30. Structural basis of human mpox viral DNA replication inhibition by brincidofovir and cidofovir.
Xu Y; Wu Y; Wu X; Zhang Y; Yang Y; Li D; Yang B; Gao K; Zhang Z; Dong C
Int J Biol Macromol; 2024 Jun; 270(Pt 2):132231. PubMed ID: 38735603
[TBL] [Abstract][Full Text] [Related]
31. An Overview of Antivirals against Monkeypox Virus and Other Orthopoxviruses.
Wang J; Shahed-Ai-Mahmud M; Chen A; Li K; Tan H; Joyce R
J Med Chem; 2023 Apr; 66(7):4468-4490. PubMed ID: 36961984
[TBL] [Abstract][Full Text] [Related]
32. Functional Assessment of 2,177 U.S. and International Drugs Identifies the Quinoline Nitroxoline as a Potent Amoebicidal Agent against the Pathogen
Laurie MT; White CV; Retallack H; Wu W; Moser MS; Sakanari JA; Ang K; Wilson C; Arkin MR; DeRisi JL
mBio; 2018 Oct; 9(5):. PubMed ID: 30377287
[No Abstract] [Full Text] [Related]
33. A systematic review to identify novel clinical characteristics of monkeypox virus infection and therapeutic and preventive strategies to combat the virus.
Chenchula S; Ghanta MK; Amerneni KC; Rajakarunakaran P; Chandra MB; Chavan M; Gupta R
Arch Virol; 2023 Jun; 168(7):195. PubMed ID: 37386209
[TBL] [Abstract][Full Text] [Related]
34. Early administration of tecovirimat shortens the time to mpox clearance in a model of human infection.
Nguyen BT; Marc A; Suñer C; Marks M; Ubals M; Hernández-Rodríguez Á; Melendez MÁ; ; Hruby DE; Russo AT; Mentré F; Mitjà O; Grosenbach DW; Guedj J
PLoS Biol; 2023 Dec; 21(12):e3002249. PubMed ID: 38127878
[TBL] [Abstract][Full Text] [Related]
35. Successful Outcome after Treatment with Cidofovir, Vaccinia, and Extended Course of Tecovirimat in a Newly-Diagnosed HIV Patient with Severe Mpox: A Case Report.
Martinez AE; Frattaroli P; Vu CA; Paniagua L; Mintz J; Bravo-Gonzalez A; Zamudio P; Barco A; Rampersad A; Lichtenberger P; Gonzales-Zamora JA
Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992234
[TBL] [Abstract][Full Text] [Related]
36. Mpox: Rapid Evidence Review.
Saguil A; Krebs L; Choe U
Am Fam Physician; 2023 Jul; 108(1):78-83. PubMed ID: 37440743
[TBL] [Abstract][Full Text] [Related]
37. Progression of human monkeypox infection despite tecovirimat in an immunocompromised adult.
Dammann F; Raja M; Camargo JF
Transpl Infect Dis; 2023 Feb; 25(1):e14022. PubMed ID: 36714983
[TBL] [Abstract][Full Text] [Related]
38. Potential use of cidofovir, brincidofovir, and tecovirimat drugs in fighting monkeypox infection: recent trends and advancements.
Rani I; Joshi H; Sharma U; Kaur J; Sood S; Ramniwas S; Chauhan A; Abdulabbas HS; Tuli HS
Naunyn Schmiedebergs Arch Pharmacol; 2024 Apr; 397(4):2055-2065. PubMed ID: 37837475
[TBL] [Abstract][Full Text] [Related]
39. A brief on new waves of monkeypox and vaccines and antiviral drugs for monkeypox.
Hung YP; Lee CC; Lee JC; Chiu CW; Hsueh PR; Ko WC
J Microbiol Immunol Infect; 2022 Oct; 55(5):795-802. PubMed ID: 36115792
[TBL] [Abstract][Full Text] [Related]
40. Treatment of Mpox with Suspected Tecovirimat Resistance in Immunocompromised Patient, United States, 2022.
Contag CA; Mische L; Fong I; Karan A; Vaidya A; McCormick DW; Bower W; Hacker JK; Johnson K; SanJuan P; Crebbin L; Temmins C; Sahni H; Bogler Y; Cooper JD; Narasimhan S
Emerg Infect Dis; 2023 Dec; 29(12):2520-2523. PubMed ID: 37856215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
